NASDAQ:NBIX - Neurocrine Biosciences Stock Price, Price Target & More

$78.16 -0.27 (-0.34 %)

(As of 04/26/2018 03:30 AM ET)

Previous Close$78.43

Today's Range$76.72 - $79.46

52-Week Range$41.76 - $92.98

Volume536,700 shs

Average Volume876,947 shs

Market Capitalization$7.31 billion

P/E Ratio-48.25

Dividend YieldN/A

Beta0.29

About Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL ? Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:NBIX

CUSIP64125C10

Webwww.neurocrine.com

Phone858-617-7600

Debt

Debt-to-Equity Ratio0.99%

Current Ratio10.20%

Quick Ratio10.20%

Price-To-Earnings

Trailing P/E Ratio-48.25

Forward P/E Ratio-339.83

P/E GrowthN/A

Sales & Book Value

Annual Sales$161.63 million

Price / Sales43.46

Cash FlowN/A

Price / CashN/A

Book Value$4.21 per share

Price / Book18.57

Profitability

EPS (Most Recent Fiscal Year)($1.62)

Net Income$-142,540,000.00

Net MarginsN/A

Return on Equity-43.46%

Return on Assets-21.65%

Miscellaneous

Employees400

Outstanding Shares89,880,000

How to Become a New Pot Stock Millionaire

Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences (NASDAQ:NBIX) released its quarterly earnings results on Tuesday, February, 13th. The company reported $0.07 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.18 by $0.11. The business had revenue of $94.52 million for the quarter, compared to analyst estimates of $94 million. During the same period last year, the firm posted ($0.51) earnings per share. View Neurocrine Biosciences' Earnings History.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Monday, April, 30th 2018. View Earnings Estimates for Neurocrine Biosciences.

What price target have analysts set for NBIX?

13 brokerages have issued 12-month price targets for Neurocrine Biosciences' stock. Their predictions range from $65.00 to $113.00. On average, they anticipate Neurocrine Biosciences' stock price to reach $95.2308 in the next year. View Analyst Ratings for Neurocrine Biosciences.

Who are some of Neurocrine Biosciences' key competitors?

Some companies that are related to Neurocrine Biosciences include Novozymes (NVZMY), bluebird bio (BLUE), Seattle Genetics (SGEN), AveXis (AVXS), Qiagen (QGEN), Bio-Techne (TECH), China Biologic Products (CBPO), Spark Therapeutics (ONCE), arGEN-X BV (ARGX), Halozyme (HALO), CRISPR Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Repligen (RGEN) and Acceleron Pharma (XLRN).

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the folowing people:

Dr. Kevin C. Gorman, CEO & Director (Age 60)
Dr. Haig P. Bozigian Ph.D., Chief Devel. Officer (Age 60)
Mr. Eric S. Benevich, Chief Commercial Officer (Age 53)
Dr. Christopher F. O'Brien, Exclusive Consultant (Age 61)
Mr. Matthew C. Abernethy, CFO & Principal Accounting Officer

Has Neurocrine Biosciences been receiving favorable news coverage?

Headlines about NBIX stock have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Neurocrine Biosciences earned a media sentiment score of 0.25 on Accern's scale. They also assigned media stories about the company an impact score of 46.31 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $78.19.

How big of a company is Neurocrine Biosciences?

Neurocrine Biosciences has a market capitalization of $7.31 billion and generates $161.63 million in revenue each year. The company earns $-142,540,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Neurocrine Biosciences employs 400 workers across the globe.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]

MarketBeat Community Rating for Neurocrine Biosciences (NBIX)

Community Ranking:		4.1 out of 5 ( )
Outperform Votes:		622 (Vote Outperform)
Underperform Votes:		133 (Vote Underperform)
Total Votes:		755

MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe NBIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Neurocrine Biosciences (NASDAQ:NBIX) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

13 Wall Street analysts have issued ratings and price targets for Neurocrine Biosciences in the last 12 months. Their average twelve-month price target is $95.2308, suggesting that the stock has a possible upside of 21.84%. The high price target for NBIX is $113.00 and the low price target for NBIX is $65.00. There are currently 13 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	2.94
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 13 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 13 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 17 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 16 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$95.2308	$95.2308	$82.3125	$69.3125
Price Target Upside:	21.84% upside	12.26% upside	1.16% upside	17.56% upside

Neurocrine Biosciences (NASDAQ:NBIX) Consensus Price Target History

Price Target History for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ:NBIX) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/10/2018	Oppenheimer	Set Price Target	Buy	$110.00	High
3/14/2018	Piper Jaffray	Reiterated Rating	Overweight	$113.00	Medium
2/22/2018	Needham & Company LLC	Reiterated Rating	Buy -> Buy	$95.00 -> $110.00	Low
2/20/2018	Leerink Swann	Boost Price Target	Outperform	$90.00 -> $96.00	Medium
2/14/2018	Deutsche Bank	Boost Price Target	Buy	$97.00	Medium
2/14/2018	JPMorgan Chase	Boost Price Target	Overweight -> Overweight	$79.00 -> $100.00	High
2/14/2018	Barclays	Reiterated Rating	Overweight	$100.00	High
1/5/2018	Jefferies Group	Boost Price Target	Buy	$105.00	Medium
11/3/2017	Robert W. Baird	Reiterated Rating	Buy	$84.00	N/A
11/2/2017	BMO Capital Markets	Boost Price Target	Positive -> Outperform	$83.00 -> $109.00	N/A
11/2/2017	Citigroup	Reiterated Rating	Buy	$79.00	N/A
8/9/2017	Cowen	Reiterated Rating	Outperform	$60.00 -> $65.00	Medium
5/15/2017	Bank of America	Reiterated Rating	Buy	$70.00	Medium
3/7/2017	Cantor Fitzgerald	Reiterated Rating	Overweight	$80.00	N/A
2/16/2017	HC Wainwright	Boost Price Target	Positive	$80.00 -> $100.00	N/A
2/10/2017	ICAP	Reiterated Rating	Outperform	$55.00	N/A
1/27/2017	CIBC	Upgrade	Market Perform -> Outperform		N/A

(Data available from 4/26/2016 forward)

Neurocrine Biosciences (NASDAQ:NBIX) Earnings History and Estimates Chart

Earnings by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ:NBIX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.01)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	($0.28)	($0.22)	($0.26)
Q2 2018	3	($0.19)	$0.33	$0.12
Q3 2018	3	($0.13)	$0.01	($0.05)
Q4 2018	3	($0.06)	$0.43	$0.18

Neurocrine Biosciences (NASDAQ NBIX) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/7/2018		($0.21)					N/A
2/13/2018	Q4 2017	$0.18	$0.07	$94.00 million	$94.52 million	View	Listen
11/1/2017	Q3 2017	($0.49)	($0.13)	$29.38 million	$60.77 million	View	N/A
8/3/2017	Q2 17	($0.67)	($0.68)	$0.61 million	$6.34 million	View	Listen
5/9/2017	Q1 17	($0.67)	($0.90)	$3.00 million		View	Listen
2/14/2017	Q416	($0.55)	($0.51)	$4.55 million		View	Listen
11/2/2016	Q316	($0.57)	($0.43)			View	N/A
8/3/2016	Q2 2016	($0.50)	($0.46)			View	N/A
5/5/2016	Q1	($0.29)	($0.22)	$15.43 million	$15.00 million	View	N/A
2/11/2016	Q415	($0.32)	($0.34)	$3.33 million		View	Listen
10/29/2015	Q315	($0.25)	($0.40)	$6.66 million		View	Listen
7/29/2015	Q2	($0.2860)	($0.28)	$0.41 million		View	Listen
4/30/2015	Q115	($0.30)	($0.01)		$19.76 million	View	N/A
2/9/2015	Q414	($0.24)	($0.26)			View	N/A
11/3/2014	Q314	($0.21)	($0.21)			View	N/A
8/6/2014	Q214	($0.18)	($0.18)	$0.12 million		View	N/A
4/30/2014	Q114	($0.19)	($0.17)	$0.78 million		View	N/A
2/6/2014	Q413	($0.17)	($0.16)	$0.79 million	$0.73 million	View	N/A
10/29/2013	Q313	($0.20)	($0.17)	$0.79 million	$0.73 million	View	N/A
7/25/2013	Q2 2013	($0.20)	($0.18)	$0.77 million	$0.73 million	View	Listen
5/2/2013	Q1 2013	($0.18)	($0.18)	$1.07 million	$0.70 million	View	Listen
2/8/2013	Q4 2012	($0.08)	$0.14	$9.43 million	$21.90 million	View	Listen
10/31/2012	Q312	($0.05)	($0.05)	$10.28 million	$9.40 million	View	N/A
7/31/2012		($0.03)	($0.01)			View	N/A
5/2/2012			($0.01)			View	N/A
2/8/2012	Q4 2011	$0.01	$0.02			View	N/A
10/31/2011		$0.19	$0.56			View	N/A
7/28/2011		$0.04	$0.04			View	N/A
5/3/2011		$0.05	$0.05			View	N/A
2/10/2011		$0.04	$0.05			View	N/A
10/28/2010	Q3 2010	$0.05	$0.06			View	N/A
7/28/2010	Q2 2010	($0.17)	($0.09)			View	N/A
4/28/2010	Q1 2010	($0.24)	($0.20)			View	N/A
2/3/2010	Q4 2009	($0.28)	($0.22)			View	N/A
10/28/2009	Q3 2009	($0.35)	($0.21)			View	N/A
7/29/2009	Q2 2009	($0.41)	($0.37)			View	N/A
5/5/2009	Q1 2009	($0.38)	($0.38)			View	N/A
2/3/2009	Q4 2008	($0.47)	($0.75)			View	N/A
10/28/2008	Q3 2008	($0.52)	($0.46)			View	N/A
7/30/2008	Q2 2008	($0.52)	($0.55)			View	N/A
4/30/2008	Q1 2008	($0.54)	($0.55)			View	N/A
2/5/2008	Q4 2007	($0.84)	($0.71)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Neurocrine Biosciences (NASDAQ:NBIX) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Neurocrine Biosciences (NASDAQ NBIX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.30%

Insider Trading History for Neurocrine Biosciences (NASDAQ:NBIX)

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ NBIX) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/5/2018	Haig P Bozigian	Insider	Sell	75,873	$90.00	$6,828,570.00	18,041
2/15/2018	Gary A Lyons	Director	Sell	5,000	$84.67	$423,350.00
2/12/2018	Dimitri E Grigoriadis	Insider	Sell	86,368	$78.32	$6,764,341.76	154,717
2/9/2018	Dimitri E Grigoriadis	Insider	Sell	71,775	$77.98	$5,597,014.50	154,717
2/6/2018	Kevin Charles Gorman	CEO	Sell	105,983	$80.25	$8,505,135.75	339,482
2/5/2018	Gary A Lyons	Director	Sell	5,000	$83.08	$415,400.00	267,066
2/5/2018	Haig P Bozigian	Insider	Sell	2,262	$83.10	$187,972.20	76,950
1/24/2018	William H Rastetter	Director	Sell	9,500	$90.00	$855,000.00	34,250
1/16/2018	Haig P Bozigian	Insider	Sell	1,625	$79.12	$128,570.00
1/16/2018	Kevin Charles Gorman	CEO	Sell	3,750	$78.89	$295,837.50
1/3/2018	Darin Lippoldt	Insider	Sell	1,979	$79.36	$157,053.44
12/28/2017	Darin Lippoldt	Insider	Sell	15,237	$75.00	$1,142,775.00
12/28/2017	Darin Lippoldt	Insider	Sell	15,237	$75.00	$1,142,775.00	28,394
12/8/2017	Darin Lippoldt	Insider	Sell	2,955	$75.00	$221,625.00	16,112
12/4/2017	Darin Lippoldt	Insider	Sell	6,279	$75.04	$471,176.16	19,436
12/1/2017	Gary A Lyons	Director	Sell	10,000	$72.92	$729,200.00	272,066
11/15/2017	Darin Lippoldt	Insider	Sell	9,900	$73.05	$723,195.00
11/8/2017	Dimitri E Grigoriadis	Insider	Sell	30,000	$74.58	$2,237,400.00	77,691
11/2/2017	Kyle Gano	Insider	Sell	24,818	$71.05	$1,763,318.90	84,596
10/2/2017	Christopher Flint Obrien	Insider	Sell	6,925	$61.04	$422,702.00	55,898
9/6/2017	Haig P Bozigian	Insider	Sell	26,250	$60.00	$1,575,000.00	144,601
9/5/2017	Christopher Flint Obrien	Insider	Sell	52,817	$57.50	$3,036,977.50	101,790
8/9/2017	Dimitri E Grigoriadis	Insider	Sell	15,354	$55.00	$844,470.00	123,045
8/4/2017	Haig P Bozigian	Insider	Sell	22,500	$50.00	$1,125,000.00	154,601
7/27/2017	Christopher Flint Obrien	Insider	Sell	8,734	$50.00	$436,700.00	57,707
5/23/2017	Dimitri E Grigoriadis	Insider	Sell	10,000	$53.39	$533,900.00	107,691
5/19/2017	Malcolm Lloyd-Smith	Insider	Sell	9,960	$53.63	$534,154.80	17,997
5/5/2017	Corinne H Nevinny	Director	Sell	5,000	$53.98	$269,900.00	34,603
5/2/2017	Dimitri E Grigoriadis	Insider	Sell	10,000	$55.00	$550,000.00	117,691
5/2/2017	Kevin Charles Gorman	CEO	Sell	21,739	$53.23	$1,157,166.97	354,346
5/1/2017	Kyle Gano	Insider	Sell	15,000	$54.00	$810,000.00	88,246
4/12/2017	Haig P Bozigian	Insider	Sell	13,065	$50.42	$658,737.30	129,805
4/12/2017	Kevin Charles Gorman	CEO	Sell	19,596	$50.42	$988,030.32	332,913
2/7/2017	Malcolm Lloyd-Smith	Insider	Sell	116	$44.61	$5,174.76
2/6/2017	Dimitri E Grigoriadis	Insider	Sell	727	$43.13	$31,355.51	115,756
2/6/2017	Kevin Charles Gorman	CEO	Sell	3,010	$43.18	$129,971.80	250,542
2/6/2017	Timothy P Coughlin	CFO	Sell	963	$43.14	$41,543.82	137,961
2/3/2017	Christopher Flint Obrien	Insider	Sell	1,500	$42.50	$63,750.00	35,044
2/3/2017	Kevin Charles Gorman	CEO	Sell	3,125	$42.55	$132,968.75	247,802
2/1/2017	William H Rastetter	Director	Sell	10,750	$42.28	$454,510.00	25,000
1/17/2017	Haig P Bozigian	Insider	Sell	1,625	$40.63	$66,023.75	114,704
1/17/2017	Kevin Charles Gorman	CEO	Sell	3,750	$40.65	$152,437.50	244,677
1/17/2017	Timothy P Coughlin	CFO	Sell	1,750	$40.65	$71,137.50	134,824
1/10/2017	Christopher Flint Obrien	Insider	Sell	1,750	$43.35	$75,862.50	31,794
1/10/2017	Kevin Charles Gorman	CEO	Sell	3,750	$43.28	$162,300.00	240,927
11/15/2016	Christopher Flint Obrien	Insider	Sell	25,000	$52.84	$1,321,000.00	30,044
9/1/2016	Malcolm Lloyd-Smith	Insider	Sell	9,000	$50.00	$450,000.00	9,000
8/15/2016	Christopher Flint Obrien	Insider	Sell	12,500	$48.73	$609,125.00	55,044
8/8/2016	Corinne H Nevinny	Director	Sell	5,000	$48.54	$242,700.00	25,555
5/25/2016	Richard F Pops	Director	Sell	15,000	$46.72	$700,800.00	15,464
5/16/2016	Christopher Flint Obrien	Insider	Sell	25,000	$45.00	$1,125,000.00	80,044
4/11/2016	Kyle Gano	Insider	Sell	41,770	$44.02	$1,838,715.40	57,788
4/6/2016	Christopher Flint Obrien	Insider	Sell	25,000	$45.00	$1,125,000.00	105,044
2/3/2016	Haig P Bozigian	Insider	Sell	1,375	$38.13	$52,428.75	111,454
2/3/2016	Kevin Charles Gorman	CEO	Sell	3,125	$38.04	$118,875.00	228,077
2/3/2016	Timothy P Coughlin	CFO	Sell	1,500	$38.06	$57,090.00	131,374
1/19/2016	Haig P Bozigian	Insider	Sell	1,625	$46.77	$76,001.25	110,079
1/19/2016	Kevin Charles Gorman	CEO	Sell	3,750	$46.70	$175,125.00	224,952
1/19/2016	Timothy P Coughlin	CFO	Sell	1,750	$46.69	$81,707.50	129,874
1/11/2016	Haig P Bozigian	Insider	Sell	1,625	$44.25	$71,906.25	108,454
1/11/2016	Kevin Charles Gorman	CEO	Sell	3,750	$44.17	$165,637.50	221,202
1/11/2016	Timothy P Coughlin	CFO	Sell	1,750	$44.25	$77,437.50	128,124
11/27/2015	Dimitri E. Grigoriadis	insider	Sell	10,000	$57.50	$575,000.00	105,308
11/9/2015	Darin Lippoldt	insider	Sell	23,761	$52.92	$1,257,432.12
10/16/2015	Haig P Bozigian	Insider	Sell	25,000	$47.78	$1,194,500.00	106,829
10/16/2015	Kevin Charles Gorman	CEO	Sell	33,500	$47.77	$1,600,295.00	217,452
9/18/2015	Gary A. Lyons	Director	Sell	15,000	$54.89	$823,350.00	252,066
7/20/2015	Dimitri E Grigoriadis	Insider	Sell	19,646	$55.00	$1,080,530.00
7/20/2015	Timothy P Coughlin	CFO	Sell	20,000	$55.00	$1,100,000.00
7/13/2015	Dimitri E Grigoriadis	Insider	Sell	10,000	$50.00	$500,000.00
7/13/2015	Timothy P Coughlin	CFO	Sell	20,000	$50.00	$1,000,000.00
6/23/2015	W Thomas Mitchell	Director	Sell	15,000	$49.35	$740,250.00
6/8/2015	Christopher Flint Obrien	Insider	Sell	10,000	$45.00	$450,000.00
6/8/2015	Timothy P Coughlin	CFO	Sell	60,000	$45.08	$2,704,800.00
3/24/2015	Gary A Lyons	Director	Sell	30,000	$41.53	$1,245,900.00
3/24/2015	Kevin Charles Gorman	CEO	Sell	40,000	$41.53	$1,661,200.00
2/10/2015	Dimitri E Grigoriadis	Insider	Sell	20,000	$35.00	$700,000.00
1/16/2015	Christopher Flint Obrien	Insider	Sell	1,750	$30.79	$53,882.50
1/16/2015	Kevin Charles Gorman	CEO	Sell	3,750	$30.79	$115,462.50
1/12/2015	Kevin Charles Gorman	CEO	Sell	3,750	$28.43	$106,612.50
1/12/2015	Kyle Gano	Insider	Sell	1,250	$28.41	$35,512.50
1/12/2015	Timothy P Coughlin	CFO	Sell	1,750	$28.37	$49,647.50
1/8/2015	Dimitri E Grigoriadis	Insider	Sell	30,000	$27.35	$820,500.00
1/8/2015	Kevin Charles Gorman	CEO	Sell	25,000	$27.39	$684,750.00
1/8/2015	Timothy P Coughlin	CFO	Sell	10,000	$27.25	$272,500.00
1/5/2015	Dimitri E Grigoriadis	Insider	Sell	2,500	$22.76	$56,900.00
1/2/2015	W Thomas Mitchell	Director	Sell	8,000	$22.79	$182,320.00
12/19/2014	Christopher Flint Obrien	Insider	Sell	20,000	$24.02	$480,400.00
12/19/2014	Kevin Charles Gorman	CEO	Sell	70,000	$23.41	$1,638,700.00
12/19/2014	Timothy P Coughlin	CFO	Sell	30,000	$23.46	$703,800.00
12/17/2014	Kyle Gano	Insider	Sell	4,957	$22.50	$111,532.50
12/15/2014	Dimitri E Grigoriadis	Insider	Sell	12,794	$22.35	$285,945.90
12/12/2014	Kyle Gano	Insider	Sell	4,043	$22.50	$90,967.50
12/11/2014	Christopher Flint Obrien	Insider	Sell	40,000	$21.82	$872,800.00
12/10/2014	Timothy P Coughlin	CFO	Sell	20,000	$21.48	$429,600.00
12/10/2014	W Thomas Mitchell	Director	Sell	7,000	$21.90	$153,300.00
11/28/2014	Timothy P Coughlin	CFO	Sell	10,000	$20.14	$201,400.00
11/24/2014	Christopher Flint Obrien	Insider	Sell	5,463	$19.53	$106,692.39
10/31/2014	Timothy P Coughlin	CFO	Sell	10,000	$19.00	$190,000.00
10/30/2014	Timothy P Coughlin	CFO	Sell	20,000	$18.31	$366,200.00
10/1/2014	W Thomas Mitchell	Director	Sell	1,275	$15.50	$19,762.50
9/15/2014	Gary A Lyons	Director	Sell	20,000	$15.66	$313,200.00
1/17/2014	Dimitri Grigoriadis	Insider	Sell	25,000	$20.00	$500,000.00	77,058
1/10/2014	Christopher Flint Obrien	Insider	Sell	6,750	$18.88	$127,440.00	96,544
1/10/2014	Kevin Charles Gorman	CEO	Sell	3,750	$18.57	$69,637.50	180,952
1/10/2014	Timothy Coughlin	CFO	Sell	1,750	$18.56	$32,480.00	97,874
1/7/2014	Dimitri Grigoriadis	Insider	Sell	25,000	$17.50	$437,500.00	75,433
1/7/2014	Kevin Charles Gorman	CEO	Sell	108,000	$16.76	$1,810,080.00	177,202
1/7/2014	Timothy Coughlin	CFO	Sell	70,000	$16.75	$1,172,500.00	96,124
9/4/2013	Kyle Gano	Insider	Sell	2,400	$15.61	$37,464.00	22,488
9/3/2013	Christopher Flint Obrien	Insider	Sell	5,000	$16.00	$80,000.00	94,794
8/21/2013	Haig Bozigian	Insider	Sell	13,999	$15.04	$210,544.96	76,954
8/21/2013	Timothy Coughlin	CFO	Sell	19,035	$15.05	$286,476.75	96,124
8/6/2013	W Thomas Mitchell	Director	Sell	1,531	$14.70	$22,505.70	1,000
8/5/2013	Haig Bozigian	Insider	Sell	11,001	$15.00	$165,015.00	76,954
8/5/2013	Timothy Coughlin	CFO	Sell	10,965	$14.99	$164,365.35	96,124
7/12/2013	Christopher Flint Obrien	Insider	Sell	5,000	$14.50	$72,500.00
6/28/2013	Christopher Flint Obrien	Insider	Sell	11,357	$13.33	$151,388.81
6/27/2013	Haig P Bozigian	Insider	Sell	8,000	$13.00	$104,000.00
6/21/2013	Dimitri E Grigoriadis	Insider	Sell	46,837	$12.51	$585,930.87

(Data available from 1/1/2013 forward)

Neurocrine Biosciences (NASDAQ NBIX) News Headlines

Source:

Date	Headline
	Neurocrine Biosciences Presents New Data Analyses at AAN Annual Meeting Demonstrating INGREZZA® Improved Tardive Dyskinesia Symptoms Across Body Regions www.prnewswire.com - April 25 at 8:31 PM
	Neurocrine Biosciences (NBIX) Given Average Rating of "Buy" by Analysts www.americanbankingnews.com - April 25 at 1:34 AM
	Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2018 Financial Results finance.yahoo.com - April 23 at 4:56 PM
	Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual ... www.prnewswire.com - April 19 at 5:15 PM
	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Neurocrine Biosciences, Inc. for Potential ... www.prnewswire.com - April 19 at 5:15 PM
	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Neurocrine Biosciences, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors finance.yahoo.com - April 19 at 8:42 AM
	Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual Meeting finance.yahoo.com - April 18 at 5:22 PM
	Brokerages Anticipate Neurocrine Biosciences (NBIX) Will Announce Quarterly Sales of $65.97 Million www.americanbankingnews.com - April 17 at 2:33 AM
	Neurocrine Biosciences (NBIX) Expected to Announce Earnings of -$0.32 Per Share www.americanbankingnews.com - April 15 at 7:17 PM
	Oppenheimer Comments on Neurocrine Biosciences' Q2 2018 Earnings (NBIX) www.americanbankingnews.com - April 13 at 8:51 AM
	Ingrezza: Boosting Neurocrine’s Top Line finance.yahoo.com - April 12 at 5:10 PM
	Neurocrine Biosciences (NBIX) Receives "Outperform" Rating from Cowen www.americanbankingnews.com - April 11 at 11:23 PM
	Neurocrine Biosciences (NBIX) Upgraded by BidaskClub to "Buy" www.americanbankingnews.com - April 11 at 8:59 PM
	Neurocrine Biosciences (NBIX) Given a $110.00 Price Target by Oppenheimer Analysts www.americanbankingnews.com - April 10 at 3:29 PM
	AbbVie : PDUFA Target Date Of Q3 For Elagolix In Endometriosis-Associated Pain www.nasdaq.com - April 10 at 9:01 AM
	A Sixth Sense For Biotech Has Made Joe Edelman A Hedge Fund Star finance.yahoo.com - April 10 at 9:01 AM
	AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain finance.yahoo.com - April 10 at 9:01 AM
	FDA needs more time to review AbbVie, Neurocrine's uterine pain drug finance.yahoo.com - April 10 at 9:01 AM
	FDA extends review for AbbVie, Neurocrine's uterine pain drug finance.yahoo.com - April 10 at 9:01 AM
	Neurocrine Biosciences (NBIX) Given "Buy" Rating at Piper Jaffray www.americanbankingnews.com - April 5 at 12:39 PM
	Neurocrine Biosciences (NBIX) Downgraded by BidaskClub www.americanbankingnews.com - April 4 at 9:30 AM
	Neurocrine Biosciences (NBIX) Rating Increased to Buy at ValuEngine www.americanbankingnews.com - April 3 at 11:38 AM
	Neurocrine Biosciences (NBIX) Stock Rating Reaffirmed by Citigroup www.americanbankingnews.com - April 2 at 12:30 AM
	Deutsche Bank Reiterates "Buy" Rating for Neurocrine Biosciences (NBIX) www.americanbankingnews.com - April 1 at 11:24 PM
	Zacks: Brokerages Anticipate Neurocrine Biosciences, Inc. (NBIX) Will Post Quarterly Sales of $66.03 Million www.americanbankingnews.com - March 31 at 1:56 AM
	Neurocrine Biosciences, Inc. (NBIX) Given Consensus Recommendation of "Buy" by Brokerages www.americanbankingnews.com - March 31 at 1:36 AM
	Neurocrine Biosciences (NBIX) Upgraded by BidaskClub to Buy www.americanbankingnews.com - March 30 at 5:40 PM
	Analysts Expect Neurocrine Biosciences, Inc. (NBIX) Will Post Earnings of -$0.32 Per Share www.americanbankingnews.com - March 29 at 11:26 PM
	Neurocrine Biosciences (NBIX) Given a $95.00 Price Target at Oppenheimer www.americanbankingnews.com - March 28 at 3:48 PM
	Needham & Company LLC Raises Neurocrine Biosciences (NBIX) Price Target to $95.00 www.americanbankingnews.com - March 28 at 2:42 PM
	Neurocrine Biosciences (NBIX) Downgraded by BidaskClub to "Buy" www.americanbankingnews.com - March 24 at 1:17 PM
	Neurocrine Biosciences (NBIX) Receives "Buy" Rating from Oppenheimer www.americanbankingnews.com - March 22 at 10:54 PM
	Loss-Making Neurocrine Biosciences Inc (NASDAQ:NBIX) Expected To Breakeven finance.yahoo.com - March 20 at 8:58 AM
	Neurocrine Biosciences, Inc. (NBIX) Expected to Post Q4 2018 Earnings of $0.43 Per Share www.americanbankingnews.com - March 16 at 12:36 PM
	FY2019 EPS Estimates for Neurocrine Biosciences, Inc. Lowered by Analyst (NBIX) www.americanbankingnews.com - March 15 at 12:42 PM
	Neurocrine Biosciences (NBIX) Rating Reiterated by Piper Jaffray Companies www.americanbankingnews.com - March 15 at 12:58 AM
	Is This AbbVie's Next Blockbuster Drug? www.msn.com - March 14 at 6:34 PM
	AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids www.prnewswire.com - March 13 at 8:55 AM
	Zacks: Analysts Expect Neurocrine Biosciences, Inc. (NBIX) to Announce -$0.32 Earnings Per Share www.americanbankingnews.com - March 12 at 9:13 PM
	Insider Selling: Neurocrine Biosciences, Inc. (NBIX) Insider Sells 75,873 Shares of Stock www.americanbankingnews.com - March 7 at 6:48 PM
	Neurocrine Biosciences to Present at Upcoming Healthcare Conferences finance.yahoo.com - March 7 at 6:01 PM
	Allianz Asset Management GmbH Boosts Stake in Neurocrine Biosciences, Inc. (NBIX) www.americanbankingnews.com - March 6 at 4:16 AM
	Neurocrine Biosciences, Inc. (NBIX) Receives Consensus Recommendation of "Buy" from Analysts www.americanbankingnews.com - March 6 at 1:36 AM
	Neurocrine Biosciences, Inc. (NBIX) Shares Sold by Sectoral Asset Management Inc www.americanbankingnews.com - March 5 at 3:35 PM
	20,000 Shares in Neurocrine Biosciences, Inc. (NBIX) Purchased by Eaton Vance Management www.americanbankingnews.com - March 5 at 10:08 AM
	Schroder Investment Management Group Lowers Position in Neurocrine Biosciences, Inc. (NBIX) www.americanbankingnews.com - March 5 at 9:02 AM
	Quotidian Technical Highlights on Selected Generic Drugs Stocks -- Mallinckrodt, Momenta Pharma, Mylan, and Neurocrine Biosciences www.bizjournals.com - March 5 at 8:45 AM
	Emory University Sells 5,537 Shares of Neurocrine Biosciences, Inc. (NBIX) www.americanbankingnews.com - March 4 at 2:59 PM
	Neurocrine Biosciences, Inc. (NBIX) Holdings Decreased by Rhumbline Advisers www.americanbankingnews.com - March 4 at 10:30 AM
	UBS Asset Management Americas Inc. Sells 54,520 Shares of Neurocrine Biosciences, Inc. (NBIX) www.americanbankingnews.com - February 28 at 5:37 PM

Neurocrine Biosciences (NASDAQ:NBIX) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Neurocrine Biosciences (NASDAQ:NBIX) Income Statement, Balance Sheet and Cash Flow Statement

Neurocrine Biosciences (NASDAQ NBIX) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff